背景:尽管胃肠道微生物群的组成改变据称是支持姜的一些治疗作用,标准化的生姜补充剂对肠道微生物群的影响尚未在人体中进行测试。
目的:为了确定标准化生姜(生姜)根粉的效果,与安慰剂相比,健康成年人的胃肠道细菌和相关结局。
方法:一项随机双盲安慰剂对照试验将18-30岁的参与者分配到生姜或微晶纤维素(MCC)安慰剂组。干预措施包括1.2g/天的生姜(每天四粒胶囊,总计84mg/天的活性姜辣素/姜辣素),为期1周,为期14天。主要结果是胃肠道社区组成,α和β的多样性,和不同的丰度,使用粪便样品的16SrRNA基因测序进行测量。次要结果是胃肠道症状,肠功能,抑郁症,焦虑,压力,疲劳,生活质量,和不良事件。
结果:n=51名参与者被纳入并分析(71%为女性;平均年龄25[SD:3]岁;生姜:n=29,安慰剂:n=22)。门的相对丰度增加更大,放线菌,与安慰剂相比,在补充生姜后观察到(U:145.0;Z:-2.1;p=0.033)。生姜与更丰富的副杆菌属有关,芽孢杆菌,Ruminococaceaeincertaesedis,未分类的芽孢杆菌,去氟科,莫甘草科,和芽孢杆菌科以及布劳特氏菌属和Sphingomonadaceae科的丰度较低(p<0.05)。补充生姜可改善消化不良症状(U:196.0;Z:-2.4;p=0.015)。生姜组和安慰剂组之间的α和β多样性以及其他次要结局没有差异。未报告中度或重度不良事件。
结论:补充姜根粉是安全的,并且改变了胃肠道细菌组成的各个方面;但是,没有改变α或β多样性,肠功能,胃肠道症状,心情,或健康成年人的生活质量。这些结果提供了关于生姜补充作用机制的进一步理解。
背景:澳大利亚新西兰临床试验注册中心(参考:ACTRN12620000302954p;https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379178&isReview=true)和治疗用品管理局(参考:CT-2020-CTN-00380-1)。
Despite compositional alterations in gastrointestinal microbiota being purported to underpin some of the therapeutic effects of ginger, the effect of a standardized ginger supplement on gut microbiota has not been tested in humans.
To determine the effect of a standardized ginger (Zingiber officinale) root powder, compared to placebo, on gastrointestinal bacteria and associated outcomes in healthy adults.
A randomized double-blind placebo-controlled
trial allocated participants aged 18 to 30 y to ginger or microcrystalline cellulose (MCC) placebo. The intervention comprised 1.2 g/d of ginger (4 capsules per day totaling 84 mg/d of active gingerols/shogaols) for 14 d following a 1-wk run-in period. Primary outcomes were gastrointestinal community composition, alpha and beta diversity, and differential abundance, measured using 16S rRNA gene sequencing of fecal samples. Secondary outcomes were gastrointestinal symptoms, bowel function, depression, anxiety, stress, fatigue, quality of life, and adverse events.
Fifty-one participants were enrolled and analyzed (71% female; mean age 25 ± 3 y; ginger: n = 29, placebo: n = 22). There was a greater increase in relative abundance of phylum, Actinobacteria, observed following ginger supplementation compared to placebo (U: 145.0; z: -2.1; P = 0.033). Ginger was associated with a greater abundance of the genera Parabacteroides, Bacillus, Ruminococcaceae incertae sedis, unclassified Bacilli, families Defluviitaleaceae, Morganellaceae, and Bacillaceae as well as lower abundance of the genus Blautia and family Sphingomonadaceae (P < 0.05). An improvement in indigestion symptoms was observed with ginger supplementation (U: 196.0; z: -2.4; P = 0.015). No differences between ginger and placebo groups were found for alpha and beta diversity or other secondary outcomes. No moderate or severe adverse events were reported.
Supplementation with ginger root powder was safe and altered aspects of gastrointestinal bacteria composition; however, it did not change alpha- or beta diversity, bowel function, gastrointestinal symptoms, mood, or quality of life in healthy adults. These results provide further understanding regarding the mechanisms of action of ginger supplementation. This
trial was registered in the Australia New Zealand Clinical Trials Registry as ACTRN12620000302954p and the Therapeutic Goods Administration as CT-2020-CTN-00380-1.